Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)

ConclusionThis is the first study designed to evaluate superiority of an IL-17A inhibitor, secukinumab, over a TNF inhibitor, SDZ-ADL, in reducing spinal radiographic progression in AS.Study RegistrationClinicalTrials.gov, NCT03259074.

http://link.springer.com/10.1007/s40261-020-00886-7

Source: Clinical Drug Investigation - January 24, 2020 Category: Drugs & Pharmacology Source Type: research